Cerevel Therapeutics Holdings, Inc. CERE
At closeJul 31, 2024, 4:00 PM EDT
52-week range unavailable
- Market cap
- 8.19B
- Shares out
- 182.20M
- Forward P/E
- -15.40
- Volume
- 15.03M
- Open
- 44.98
- Previous close
- 44.96
- Day's range
- 44.96 – 44.99
- Beta
- 1.41
- Analysts
- Hold
- Price target
- 43.40 (-3.5%)
- Earnings date
- Aug 7, 2024
1M +3.73 (+9.05%)
Key statistics
- Enterprise value
- 7.83B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 14.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -212.07M
- Total cash
- 846.29M
- Total debt
- 482.30M
- Return on equity
- -92.45%
- Short % of float
- 6.88%
- 50-day average
- 41.63
- 200-day average
- 39.55
Analyst view
Consensus: hold
- Target (low)
- 31.00
- Target (mean)
- 43.40
- Target (high)
- 45.00
- Strong buy0
- Buy0
- Hold9
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.80.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 7, 2024 | Jun 1, 2024 | -0.58 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.61 | — | — | — |
| Feb 27, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 1, 2023 | Sep 1, 2023 | -0.63 | — | — | — |
| Aug 2, 2023 | Jun 1, 2023 | -0.65 | — | — | — |
| May 3, 2023 | Mar 1, 2023 | -0.67 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 27, 2023 | Piper Sandler | init | — | Overweight |
| Aug 6, 2023 | Mizuho | main | Neutral | Neutral |
| Aug 2, 2023 | Morgan Stanley | main | Overweight | Overweight |
| Aug 2, 2023 | B of A Securities | down | Buy | Neutral |
| Aug 2, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| May 22, 2023 | Goldman Sachs | main | Neutral | Neutral |
About Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts. As of August 1, 2024, Cerevel Therapeutics Holdings, Inc. operates as a subsidiary of AbbVie Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cerevel.com
News
CERE DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE 
CERE Investors Have the Opportunity to Lead the Cerevel Securities Fraud Lawsuit with Faruqi & Faruqi, LLP 
FINAL REMINDER CERE DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Cerevel Therapeutics Holdings, Inc. Investors to Participate in the Class Action Lawsuit 
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit 
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics 
FINAL CERE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cerevel Therapeutics Holdings, Inc. Investors to Join the Class Action Lawsuit 
CERE FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE 
CERE DEADLINE TUESDAY: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE 
CERE STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! 
CERE IMPORTANT DEADLINE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
Your note
Sign in to keep a note on CERE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COLES NEAVELLE ANTHONY | Director | Sale | Jun 30, 2024 | 25,928 |
| DEKKERS MARIJN E | Director | Stock Award(Grant) | Jun 4, 2024 | 444,609 |
| GIORDANO DOUGLAS E | Director | Stock Award(Grant) | Jun 4, 2024 | 13,743 |
| GORDON CHRISTOPHER R | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 4, 2024 | 65,693,500 |
| KOPPEL ADAM M | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 4, 2024 | 65,693,500 |
| MCKERNAN RUTH | Director | Stock Award(Grant) | Jun 4, 2024 | 13,743 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bain Capital Investors, LLC | 38.23% | 60,199,729 | 1.91B | Jun 29, 2023 |
| FMR, LLC | 14.92% | 23,493,789 | 746.87M | Jun 29, 2023 |
| Perceptive Advisors Llc | 6.41% | 10,088,385 | 320.71M | Jun 29, 2023 |
| Vanguard Group Inc | 3.60% | 5,662,550 | 180.01M | Jun 29, 2023 |
| Price (T.Rowe) Associates Inc | 3.32% | 5,224,800 | 166.10M | Jun 29, 2023 |
| Blackrock Inc. | 3.07% | 4,832,707 | 153.63M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 3.66% | 5,768,842 | 136.72M | Aug 30, 2023 |
| Price (T.Rowe) Health Sciences Fund | 1.22% | 1,929,050 | 61.32M | Jun 29, 2023 |
| Fidelity Growth Company K6 Fund | 1.16% | 1,829,327 | 59.64M | May 30, 2023 |
| Vanguard Total Stock Market Index Fund | 1.14% | 1,797,051 | 57.13M | Jun 29, 2023 |
| Price (T.Rowe) New Horizons Fund | 1.11% | 1,747,006 | 55.54M | Jun 29, 2023 |
| Fidelity Series Growth Company Fund | 1.08% | 1,695,459 | 40.18M | Aug 30, 2023 |